NSD1 Inhibitors

NSD1, also known as Nuclear receptor binding SET domain protein 1, is a histone methyltransferase that plays a critical role in epigenetic regulation by methylating histone proteins. Dysregulation of NSD1 has been associated with various diseases, including cancer. To identify NSD1 inhibitors, researchers have explored a range of chemical compounds that target specific epigenetic mechanisms and pathways to modulate NSD1 expression. One class of NSD1 inhibitors includes compounds that target histone methyltransferases or demethylases. GSK126, for example, is a specific inhibitor of EZH2, an enzyme involved in histone methylation. Inhibition of EZH2 can indirectly impact NSD1 by altering histone methylation patterns, leading to downregulation of NSD1 expression through epigenetic regulation. Similarly, EPZ-5676 and UNC1999 target other histone methyltransferases (DOT1L and G9a, respectively), and their inhibition can also influence NSD1 expression through epigenetic mechanisms. Chemical compounds like SGC0946 and 3-Deazaneplanocin A (DZNep) inhibit histone demethylases (LSD1 and EZH2, respectively). Inhibition of these demethylases indirectly modulates NSD1 by affecting the balance of histone methylation marks, leading to epigenetic regulation of NSD1 expression.

Another class of NSD1 inhibitors includes bromodomain inhibitors like JQ1, which target proteins like BRD4 involved in transcriptional regulation. Inhibition of BRD4 can indirectly impact NSD1 by affecting chromatin accessibility and transcriptional regulation at the NSD1 gene locus. Furthermore, inhibitors like A-196 and ML324 target specific lysine-specific demethylases (KDM5C and PRMT5, respectively). Inhibition of these demethylases indirectly influences NSD1 expression by affecting histone methylation or arginine methylation of proteins, leading to epigenetic regulation of NSD1. Additionally, inhibitors like SGC707 and CPI-455 target the histone demethylase KDM6A (UTX) and EZH2, respectively. Their inhibition can indirectly influence NSD1 expression through epigenetic regulation. Lastly, PFI-2 and UNC1215 are inhibitors of the histone methyltransferases SETD7 and G9a, respectively. Inhibition of these enzymes can indirectly affect NSD1 expression by modulating the methylation of histones and other proteins, leading to epigenetic regulation. In summary, NSD1 inhibitors encompass a diverse group of chemicals that target specific epigenetic mechanisms and pathways to modulate NSD1 expression.